Translational biomarkers of the DREAM study (a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in

Project Details

StatusFinished
Effective start/end date1/07/1930/06/20

Funding

  • AstraZeneca: AUD77,974.00
  • AstraZeneca: AUD77,126.00